Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0UWYGQ
ADC Name
WO2021115426A1 ADC-4
Synonyms
WO2021115426A1 ADC 4
   Click to Show/Hide
Organization
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Drug Status
Investigative
Indication
In total 2 Indication(s)
Gastric cancer [ICD11:2B72]
Investigative
Pancreatic cancer [ICD11:2C10]
Investigative
Drug-to-Antibody Ratio
4.06
Structure
Antibody Name
h1902-11
  Antibody Info 
Antigen Name
Claudin-18.2 (CLDN18.2)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
WO2021115426A1 ADC-4 linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
1.9
nM
SK-BR-3 cells
Breast adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.90 nM Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description
Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
References
Ref 1 Anti-claudin antibody-drug conjugate and pharmaceutical use thereof; 2021-06-17.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.